Phaseline

Targets › RAMP1

RAMP1 (Receptor activity-modifying protein 1): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Neurology; next expected readout Aug 2027.

Accessory protein that interacts with and modulates the function of G protein-coupled receptors including calcitonin gene-related peptide type 1 receptor (CALCRL) and calcitonin receptor (CALCR). Required for the transport of CALCRL to the plasma membrane. (UniProt, O60894)

Open in Phaseline: the race on RAMP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerZavegepant (PF-07930207)
Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist
RAMP1, CALCRLPhase 1Acute Treatment of Migraine; MigraineAug 2027

Conditions

Acute Treatment of Migraine (1) Migraine (1)

Modalities

small molecule (1)

Companies

Pfizer (1)

Related targets

CALCRL (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.